INTRODUCTION 104
Western diet and lifestyle account for up to 80% of colorectal cancer (CRC) incidence. 1 
105
Numerous specific factors are proposed to explain this association, and their influence on the 106 gut microbiome as a factor in CRC risk is a longstanding hypothesis. 2 The interplay between gut 107 bacterial composition and host epithelium is recognized in local immune function, metabolism, 108 and host health, including an hypothesized role in susceptibility to gastrointestinal and other 109 cancers.
3, 4 Reported differences in the gut microbiome, including microbial community 110 composition, between healthy and tumor tissues support disturbances in intestinal bacteria 111 associated with CRC. 5 This includes evidence of dense colonies of bacteria (i.e., biofilms) 112 invading the mucus layer in association with colonic adenoma and cancers, particularly of the 113 right colon, that in vitro exhibit tumor-promoting effects. Several hypotheses are proposed to explain a role for gut bacteria in CRC, including the 124 tumorigenic activity of secondary bile acids [e.g., deoxycholic acid (DCA)] produced by bacterial 125 bile salt hydrolases in the large intestine. 2, [8] [9] [10] Outstanding interest in a bile acid-CRC 126 hypothesis led us to investigate ursodeoxycholic acid (UDCA): a therapeutic bile acid based on 127 evidence of preventive activity in mouse models of colon carcinogenesis, 11 favorable effects of 128 UDCA on bile acid pools including DCA-lowering activity, 12 reports of lower CRC risk in patients 129 receiving UDCA for other indications 13, 14 and recent evidence that dysbiosis in the gut 130 microbiome of patients with primary biliary cirrhosis (PBC) may be modified by treatment with 131 UDCA. 15 In our phase III placebo-controlled, randomized trial of UDCA, we observed no effect 132 of UDCA on adenoma overall at follow-up, but we noted reduction in adenoma with high-grade 133 dysplasia. 16 Subsequently, we showed reduced risk for large and advanced adenoma in men 134 randomized to UDCA, and evidence for increased risk among younger and obese women,implicating sex as an important variable in UDCA activity. 17 Since completing this trial, evidence 136 for sexual dimorphism in bile acid metabolism in mice 18 and bile acid effects on gut bacterial 137 composition 19 have emerged, prompting us to evaluate UDCA for its effects on the microbiome 138 and adenoma outcomes, with consideration for sex. We used archival paired stool specimens 139 from a subset of participants in the UDCA trial to test the effect of UDCA on the microbiome and 140 conduct exploratory analyses to relate microbiome measures to adenoma outcomes. 141
MATERIALS AND METHODS 142
Study group, sample collection, study design 143
As part of the Arizona phase III placebo-controlled trial of 8-10 mg/kg of body weight 144 UDCA for the prevention of colorectal adenomas, stool samples were obtained from participants 145 who consented to fecal bile acid analysis. 20, 21 Briefly, eligible individuals had at least one 146 colorectal adenoma with a diameter of ≥3 mm removed during a colonoscopy within six months 147 before registration. A total of 1,285 participants were randomized to UDCA (n = 661) or placebo 148 (n = 624), of whom 1,192 (613 UDCA and 579 placebo) completed the trial. The primary trial 149 endpoint was colorectal adenoma, defined as the occurrence of one or more adenoma or 150 adenocarcinoma at colonoscopy performed ≥ 6 months after the qualifying colonoscopy. 151
Advanced adenomas were defined as previously described as those with adenocarcinoma, 152 high-grade dysplasia, villous/tubulovillous histology, or a diameter ≥ 1 cm.
17 All stools passed 153 over a 72-hour period were collected in a single metal container on ice. Pooled 72-hour 154 samples were transported at 4 o C to the laboratory where fecal solid was separated from fecal 155 water as previously described. 20, 21 Separated fecal water and solid stool were stored at -80°C 156 for an average of 15 years until processing for microbial DNA. 157
158
For the current study, only participants with paired baseline (pre-intervention with UDCA 159 or placebo) and end-of-study microbiome sequence data and adenoma outcome data were 160 included. A total of 401 participants (198 UDCA and 203 placebo) Jaccard distance, and Bray-Curtis dissimilarity -measures of microbiome composition 186 dissimilarity) and principal coordinate analysis (PCoA) were estimated using q2-diversity after 187 samples were rarefied (i.e., subsampled without replacement) to 900 sequences per sample. 188
Taxonomy was assigned to ASVs using classify-sklearn (via q2-feature-classifier) against the 189 Greengenes 13_8 99% OTUs reference sequences treatment group, overall and stratified by sex, was tested for difference from zero using a one-208 sample t-test with Benjamini-Hochberg false discovery rate (FDR) correction. 34 We additionally 209 applied pairwise tests to determine if UDCA treatment was associated with changes in gut 210 microbial community richness (i.e., changes in the number of bacterial taxa present in the 211 community). This was performed by comparing change in Observed OTUs and Faith's 212
Phylogenetic Diversity on a per subject basis in the two treatment groups. 213
We performed ANCOM 35 and Wilcoxon signed-rank tests comparing species abundance 214 at baseline and end-of-study in both UDCA-treated and placebo groups. ANCOM tests were 215 performed to assess differences within the whole bacterial community in each arm separately. 216
Wilcoxon signed-rank tests were additionally performed on 18 individual bacterial genera, the 217 order Bifidobacteriales, and the ratio of the Firmicutes to Bacteroidetes phyla abundances, all of 218 which have been previously associated with CRC or its risk factors. 219
Associations between change in each microbiome measure and adenoma outcome (any 220 adenoma or advanced adenoma) were tested in each arm separately using Poisson regression, 221 adjusted for sex, age, aspirin use, baseline microbiome measure, and an indicator for whether a 222 participant's paired baseline and end-of-study DNA samples were processed in different 223 batches. Potential interactions between microbiome measures and UDCA on recurrence were 224 tested using likelihood ratio tests. These statistical tests were performed with Stata 14.2 225 (StataCorp, College Station, TX).
RESULTS

227
Participant characteristics 228
Characteristics of the 401-participant subgroup with complete sequence data and adenoma 229 outcome status were compared to participants in the parent trial not included in the microbiome 230 study, by treatment assignment ( Table 1 ). The placebo subsample had fewer aspirin users (chi-231 square test, P = 0.004), the largest adenomas (Wilcoxon rank-sum test, P = 0.040), and greater 232 adenoma number at baseline (Wilcoxon rank-sum test, P = 0.004) than the placebo parent 233 study. Compared to the parent trial, the UDCA subsample included more male participants (chi-234 square test, P = 0.016). Within the subsample, the UDCA arm included more males (chi-square 235 test, P = 0.024) and more aspirin users (chi-square test, P = 0.003) than the placebo arm. 236 237
Microbiome composition is not correlated with storage time 238
After separation from fecal water, solid stool samples used in this study were stored at -80 o C for 239 varying lengths of time before microbiome sequencing. Baseline samples were stored for an 240 average of 17.2 ± 1.1 years, and end-of-study samples were stored for an average of 14.6 ± 1.1 241 years. There was no significant difference in storage time by treatment arm (P= 0.22). 242
Furthermore, no significant correlations were observed between storage time and any of the 243 diversity metrics at baseline or end-of-study. Lack of evidence for storage time effects on these 244 measures is in agreement with published studies supporting long-term freezing as an effective 245 preservation method for studies of microbiome composition. Figure 1A) . Distances between paired samples from the same subject were smaller than 250 distances between samples from different subjects in both treatment groups ( Figure 1B) . 251
Intraclass correlation coefficients estimated separately for each of the four beta-diversity metrics 252 ranged from 0.50 to 0.68 for the placebo group, and from 0.39 to 0.73 for the UDCA group 253 ( Figure 1B) . There was no clear pattern of change in composition between the UDCA and 254 placebo arms in terms of the magnitude of the four measures applied to assess microbial 255 community composition (U = 19292.00, P = 0.244) (Figure 1C) , suggesting that both treatment 256 groups experience a similar amount of microbiome change between baseline and end-of-study.
Given the amount of microbiome changes from baseline to end-of-study appeared 258 similar between placebo and intervention, we next tested whether individuals in either arm 259 experienced changes in their microbiome that were more similar to one another. Paired one-260 sample t-tests were used to identify consistent changes across individuals in four microbial 261 community distance metrics (Figure 2A-D) and two microbial community richness metrics 262 (Figure 2E-F) . In this analysis, UDCA treatment was associated with a shift in microbial 263 community distance metrics according to PC1 of unweighted UniFrac (t = -4.393, P < 0.001) 264 distance, and PC1 of both unweighted (Jaccard: t = -5.697, P < 0.001) and weighted (Bray-265 Curtis; t = -2.699, P = 0.035) non-phylogenetic metrics. These shifts were not observed in the 266 placebo arm. These results suggest that while gut microbial communities changed by a similar 267 degree in both UDCA and placebo groups ( Figure 1C) , individuals in the UDCA arm 268 experienced changes that were more similar to each other (i.e. 'UDCA-associated') than those 269 in the placebo arm (Figure 2B-D) . For gut microbial community richness (i.e., changes in the 270 number of bacterial taxa present in the community), Observed OTUs and Faith's Phylogenetic 271
Diversity were computed on a per-subject basis in each arm (Figure 2 E-F) . The average 272 change was not significantly different from zero in either arm for either measure (all P > 0.05). 273
Therefore, despite UDCA-induced changes in overall community composition, we found no 274 evidence that UDCA treatment significantly altered gut microbial community richness. In other 275 words, the significant compositional changes observed with UDCA treatment support alterations 276 to relative abundance and even presence/absence of microbial species, but not the number of 277 different types of organisms present in the gut microbiome. 278
Because UDCA treatment was shown to be protective against the development of 279 adenoma in males but not females in the parent trial, 17 we next explored results stratified by sex 280 (Figure 3A-F) . Using a pairwise approach, two of the six microbiome measures showed a 281 statistically significant change with UDCA treatment in males [unweighted UniFrac (t = -4.393, P 282 < 0.001) and Jaccard (t= -5.234, P < 0.001)]. For females, none of the metrics showed a 283 significant change with UDCA, likely due to the smaller sample size (48 women versus 150 284 men), as the mean change in PC1 was the same for females and males. As in the total sample, 285 no systematic changes were observed for males or females in the placebo arm. 286
With the observed changes in community composition in response to UDCA treatment, 287
we were interested in identifying bacterial taxa that exhibited abundance changes. ANCOM 288 tests indicated that no bacterial genera or ASVs consistently differed between baseline and end-289 of-study measurements in the placebo group. In the UDCA treatment arm, ANCOM tests on all 290
ASVs showed that the relative abundance of Faecalibacterium decreased between baseline andend-of-study. Paired Wilcoxon signed-rank tests were additionally performed on 18 individual 292 bacterial taxa that contain species or strains previously associated with CRC, 37 as well as for 293 the genus Bifidobacterium (see Supplemental Table 1 ). Of these, Streptococcus (FDR-294 corrected P = 0.003), Escherichia (FDR-corrected P = 0.003), and Bilophila (FDR-corrected P = 295 0.012) were found to have increased significantly, while Fusobacterium (FDR-corrected P = 296 0.049) decreased in relative abundance between baseline and end-of-study in UDCA-treated 297 subjects. There were no significant changes for these genera in the placebo arm (all FDR-298 corrected P > 0.05). We additionally tested whether the ratio of the Firmicutes to Bacteriodetes 299 phylum abundances changed with treatment using Wilcoxon signed-rank tests, but did not find 300 evidence for this in either treatment group (UDCA: W=10369.5, FDR-corrected P = 0.57; 301 placebo: W=9081.0, FDR-corrected P = 0.13). 302
303
Change in microbiome and adenoma recurrence. 304
We next assessed whether UDCA-associated changes in community composition, when 305 controlled for the baseline value, were associated with adenoma development. We found no 306 evidence that change in any of the four microbial community distance metrics from baseline to 307 end-of-study were associated with risk of adenoma in either treatment arm (all P> 0.05) even 308 after considering effects by sex separately. For the specific ASVs that were shown to increase 309 with UDCA treatment (i.e., Streptococcus, Escherichia, Bilophila and Fusobacterium), we found 310 no evidence of association between any of these ASVs and adenoma outcome in either the 311 placebo or UDCA arm (all P >0.05). 312
Utilizing six metrics of microbiome diversity and richness, we assessed whether daily 315 oral UDCA (6-8 kg/m 2 ) given for an average of 3 years for the prevention of colorectal adenoma 316 significantly changed the gut microbiome. Secondarily, we investigated whether change in these 317 microbiome measures were associated with adenoma risk by treatment arm considering sex as 318 a modifying factor of UDCA chemoprevention benefit. Our results show participants randomized 319 to UDCA exhibited non-random changes in their microbiome diversity. However, the UDCA 320 associated changes were not associated with any chemopreventive action of UDCA for 321 adenoma risk. We observed no significant effect of UDCA on species richness (number of 322 observed ASVs, a corollary of the number of species present) or phylogenetic richness of 323 microbial communities nor UDCA-related changes in abundance-weighted UniFrac phylogenetic 324 diversity metrics (which is biased toward detecting changes in distantly related community 325 members that are present in high relative abundance, discussed below). Further, while theobserved effects on the microbiome reached significance in the larger sample size of men, the 327 overall pattern of change was similar for women. Our results do not support UDCA effects on 328 the microbiome as a mediator of chemopreventive activity nor do we find evidence of differential 329 effects of UDCA on the gut microbiome by sex as an explanation for our previous finding of 330 chemopeventive effects of UDCA for adenoma in men but not women. 331
Microbial communities in participants randomized to UDCA differed in their composition, 332 particularly in PC1, as measured by unweighted but not weighted UniFrac. Unweighted UniFrac 333 is a measure of the degree of phylogenetic similarity between two microbial communities not 334 considering abundance of ASVs, and, hence, is equally sensitive to differences in low-and high-335 abundance ASVs. In contrast, weighted UniFrac accounts for ASV abundances when 336 comparing microbial community composition between samples and is therefore more sensitive 337 to detecting changes in high-abundance ASVs. Both UniFrac metrics are designed to up-weight 338 changes in phylogenetically dissimilar ASVs relative to phylogenetically similar ASVs. Thus, our 339 observation of a significant change in unweighted UniFrac and no significant change in 340 weighted UniFrac suggests that overall distantly related, but lower abundance, ASVs changed 341 with UDCA. 342
Bray-Curtis (abundance-weighted) and Jaccard dissimilarity measures are the non-343 phylogenetic analogs to weighted and unweighted UniFrac, respectively; they measure the 344 degree to which two microbial communities share ASVs, rather than the degree of phylogenetic 345 relatedness between communities. We observed a significant change in Bray-Curtis distance. 346
Together with no significant change in weighted UniFrac, our results suggest that high 347 abundant, phylogenetically similar ASVs are changing with UDCA. As Jaccard distance is not 348 phylogenetically or abundance weighted, it limits interpretation of the results and implies only 349 that some ASVs are changing. By comparing our results across these four metrics, we can gain 350 some insight into categories of microbial community members that are changing in response to 351 UDCA. Specifically, our results suggest that distantly related, low-abundance ASVs as well as 352 closely related, high-abundance ASVs (but not distantly related, high-abundance ASVs) are 353 changed with UDCA treatment. 354
To gain insight on how the observed UDCA changes related to changes in the 355 taxonomic composition of the gut microbiome, we evaluated the bacterial phyla and genera 356 most strongly associated with PC1. This was achieved by computing Spearman correlation 357 coefficients between the phyla and genera that were observed at least one time in at least 50% 358 of the 802 pre-and post-treatment microbiome samples. For most metrics, change in PC1 was 359 associated with an increase in the Bacteriodetes relative abundance and a decrease in the 360 earlier studies, including our own, showing that UDCA led to increases in the levels of DCA in 376 aqueous and solid stool fractions, with evidence that UDCA may enhance fecal bile acid levels 377 through inhibitory effects on 7-α-dehydroxylation of cholic acid. As such, expansion of Bilophila 378 would be expected but perhaps not desirable given pro-inflammatory effects of Bilophila 379 wadsworthia in mice. Increases in members of the genera Streptococcus and Escherichia with 380 UDCA may similarly reflect response to changes in the bile acid pool in stools of UDCA 381 subjects. At the 16S RNA level we are unable to assess effects on select strains of bacteria. For 382 example, we are unable to determine the effects of UDCA on streptococcal lactic acid bacteria 383 thought to have anti-mutagenic/anti-cancer properties in human intestine, 42 from subspecies of 384 Streptococcus gallolyticus that have been associated with colon cancer proliferation and 385 growth.
43 Importantly, we are unable to test for any UDCA effect on E. coli strains harboring the 386 polyketide synthase (pks) genomic island, which encodes for the genotoxin colibactin, and has 387 been identified in cancer and inflammatory bowel disease and shown to promote tumor 388 development in inflammatory mouse models. 44, 45 Interesting is the observed UDCA reduction in 389 Missing data: race, n = 24 (1.9%); education, n = 29 (2.3%); ever smoker, n = 37 (2.9%); BMI, n 444 = 29 (2.3%); previous polyp, n = 76 (5.9%); largest adenoma, n = 1 (0.1%); proximal adenoma, 445 n = 3 (0.2%); villous histology, n = 2 (0.2%) 446 447 Largest adenoma (mm), mean ± SD; median 9.6 ± 6.3; 8 8.4 ± 5.4; 7.5 8.9 ± 5.4; 8 8.7 ± 5.4; 8
Number of adenomas, mean ± SD; median 1.6 ± 0.9; 1 1.5 ± 0.8; 1 1.7 ± 1.1; 1 1.6 ± 0.9; 1 
